LT4677B - Vandeninė suspensija, vartotina per nosį - Google Patents

Vandeninė suspensija, vartotina per nosį Download PDF

Info

Publication number
LT4677B
LT4677B LT99-100A LT99100A LT4677B LT 4677 B LT4677 B LT 4677B LT 99100 A LT99100 A LT 99100A LT 4677 B LT4677 B LT 4677B
Authority
LT
Lithuania
Prior art keywords
suspension
loteprednol etabonate
nasal
aqueous
aqueous suspension
Prior art date
Application number
LT99-100A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT99100A (en
Inventor
Koji Doi
Original Assignee
Bodor,Nicholas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor,Nicholas filed Critical Bodor,Nicholas
Publication of LT99100A publication Critical patent/LT99100A/xx
Publication of LT4677B publication Critical patent/LT4677B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
LT99-100A 1997-01-16 1999-08-12 Vandeninė suspensija, vartotina per nosį LT4677B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1966497 1997-01-16

Publications (2)

Publication Number Publication Date
LT99100A LT99100A (en) 2000-02-25
LT4677B true LT4677B (lt) 2000-07-25

Family

ID=12005518

Family Applications (1)

Application Number Title Priority Date Filing Date
LT99-100A LT4677B (lt) 1997-01-16 1999-08-12 Vandeninė suspensija, vartotina per nosį

Country Status (33)

Country Link
US (1) US6368616B1 (id)
EP (1) EP0973501B1 (id)
KR (1) KR100471708B1 (id)
CN (1) CN1126535C (id)
AR (1) AR011773A1 (id)
AT (1) ATE249205T1 (id)
AU (1) AU730953C (id)
BR (1) BR9806771A (id)
CA (1) CA2278025C (id)
CZ (1) CZ294919B6 (id)
DE (1) DE69818026T2 (id)
DK (1) DK0973501T3 (id)
EA (1) EA001775B1 (id)
ES (1) ES2206880T3 (id)
HK (1) HK1026138A1 (id)
HU (1) HU226613B1 (id)
ID (1) ID21892A (id)
IL (1) IL130979A0 (id)
LT (1) LT4677B (id)
LV (1) LV12449B (id)
MX (1) MXPA99006628A (id)
NO (1) NO324619B1 (id)
NZ (2) NZ336990A (id)
PL (1) PL190753B1 (id)
PT (1) PT973501E (id)
RS (1) RS49701B (id)
SI (1) SI20057A (id)
SK (1) SK283164B6 (id)
TR (1) TR199901663T2 (id)
TW (1) TW503113B (id)
UA (1) UA52722C2 (id)
WO (1) WO1998031343A2 (id)
ZA (1) ZA98303B (id)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
DK1025859T3 (da) * 1998-08-26 2006-10-16 Teijin Ltd Pulverformige pernasale præparater
DE19947235A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
RU2358699C2 (ru) * 2001-06-18 2009-06-20 Ноувен Фамэсьютикэлз, Инк. Композиция для чрескожной доставки лекарственного средства (варианты), способ ее получения и использование
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
ES2339351T3 (es) 2003-06-19 2010-05-19 Nicholas S. Bodor Mejora de la actividad y/o duracion de la accion de esteroides anti-inflamatorios blandos para la aplicacion topica u otra local.
CA2558941C (en) * 2003-06-19 2012-05-15 Nicholas S. Bodor Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
EP1744759B1 (en) 2004-03-25 2009-09-02 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
WO2013043387A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액

Also Published As

Publication number Publication date
AR011773A1 (es) 2000-09-13
UA52722C2 (uk) 2003-01-15
ES2206880T3 (es) 2004-05-16
EP0973501B1 (en) 2003-09-10
EP0973501A2 (en) 2000-01-26
NO324619B1 (no) 2007-11-26
TR199901663T2 (xx) 1999-09-21
WO1998031343A2 (en) 1998-07-23
NZ509908A (en) 2004-12-24
NO993453L (no) 1999-07-13
AU730953C (en) 2002-02-07
MXPA99006628A (es) 2005-01-10
WO1998031343A3 (en) 1998-09-17
HK1026138A1 (en) 2000-12-08
AU5495298A (en) 1998-08-07
LT99100A (en) 2000-02-25
AU730953B2 (en) 2001-03-22
LV12449A (lv) 2000-04-20
US6368616B1 (en) 2002-04-09
KR100471708B1 (ko) 2005-03-07
SK283164B6 (sk) 2003-03-04
NZ336990A (en) 2001-03-30
ZA98303B (en) 1998-07-20
EA001775B1 (ru) 2001-08-27
SK94899A3 (en) 2000-05-16
CN1126535C (zh) 2003-11-05
CA2278025A1 (en) 1998-07-23
RS49701B (sr) 2007-12-31
EA199900659A1 (ru) 2000-02-28
ID21892A (id) 1999-08-05
LV12449B (en) 2000-09-20
SI20057A (sl) 2000-04-30
CA2278025C (en) 2005-09-06
CZ294919B6 (cs) 2005-04-13
ATE249205T1 (de) 2003-09-15
IL130979A0 (en) 2001-01-28
TW503113B (en) 2002-09-21
BR9806771A (pt) 2000-05-16
PL334614A1 (en) 2000-03-13
CZ237499A3 (cs) 2000-01-12
CN1250370A (zh) 2000-04-12
KR20000070214A (ko) 2000-11-25
PL190753B1 (pl) 2006-01-31
DE69818026D1 (de) 2003-10-16
NO993453D0 (no) 1999-07-13
DK0973501T3 (da) 2004-01-19
PT973501E (pt) 2004-02-27
YU36199A (sh) 2002-09-19
DE69818026T2 (de) 2004-07-08
HUP0002473A2 (hu) 2000-12-28
HU226613B1 (en) 2009-04-28
HUP0002473A3 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
LT4677B (lt) Vandeninė suspensija, vartotina per nosį
ES2626134T3 (es) Composiciones de bepotastina
JP3683595B2 (ja) セチリジン含有抗アレルギー点眼点鼻用組成物
JP5549669B2 (ja) 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法
JP2001187728A (ja) 眼科用組成物
JP3597333B2 (ja) 急性鼻炎を処置するための医薬製剤
CA2159288A1 (en) Aqueous nasal suspension
KR20150018509A (ko) 점막용 조성물
NZ537186A (en) Nasal compositions comprising a mucopolysaccharide and propylene glycol
JP4453987B2 (ja) 点鼻用水性懸濁液
JP2003055201A (ja) ビタミンａ類含有可溶化組成物及びビタミンａ類の安定化方法
JP2001131055A (ja) 液剤、液剤の白濁解消方法及び液剤の経粘膜吸収促進方法
JPH08151332A (ja) 点鼻用水性懸濁液
JP2007077143A (ja) アシタザノラスト含有組成物
JP2002037735A (ja) カフェイン類の安定化方法および粘膜適用組成物
JPH1036255A (ja) 眼圧降下用点眼剤
JP2005075735A (ja) オキシメタゾリン含有組成物
WO2022035388A1 (en) Pharmaceutical compositions comprising azelastine and relevant excipients
TR2023001620T2 (tr) Azelasti̇n ve i̇lgi̇li̇ eksi̇pi̇yanlari i̇çeren farmasöti̇k kompozi̇syonlar
JP2006069946A (ja) 微量定量噴霧用の水性懸濁剤
NZ616149B2 (en) Nasal Pharmaceutical Formulation Comprising Fluticasone

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20100114